CoChat

Compounds activating VCP D1 ATPase enhance both autophagic and proteasomal neurotoxic protein clearance

Wrobel, Lidia, Hill, Sandra M., Djajadikerta, Alvin, Fernandez-Estevez, Marian, Karabiyik, Cansu, Ashkenazi, Avraham, Barratt, Victoria J., Stamatakou, Eleanna, Gunnarsson, Anders, Rasmusson, Timothy, Miele, Eric W., Beaton, Nigel, Bruderer, Roland, Feng, Yuehan, Reiter, Lukas, Castaldi, M. Paola, Jarvis, Rebecca, Tan, Keith, Bürli, Roland W., Rubinsztein, David C. · 2022 · Nature Communications
Cited by 49

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Enhancing the removal of aggregate-prone toxic proteins is a rational therapeutic strategy for a number of neurodegenerative diseases, especially Huntington’s disease and various spinocerebellar ataxias. Ideally, such approaches should preferentially clear the mutant/misfolded species, while having minimal impact on the stability of wild-type/normally-folded proteins. Furthermore, activation of both ubiquitin-proteasome and autophagy-lysosome routes may be advantageous, as this would allow effective clearance of both monomeric and oligomeric species, the latter which are inaccessible to the proteasome. Here we find that compounds that activate the D1 ATPase activity of VCP/p97 fulfill these requirements. Such effects are seen with small molecule VCP activators like SMER28, which activate autophagosome biogenesis by enhancing interactions of PI3K complex components to increase PI(3)P production, and also accelerate VCP-dependent proteasomal clearance of such substrates. Thus, this mode of VCP activation may be a very attractive target for many neurodegenerative diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-31905-0

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 68

  1. Balchin, D., Hayer-Hartl, M. & Hartl, F. U. In vivo aspects of protein folding and quality control. Science 353, aac4354 (2016). · DOI · Paper page
  2. Dikic, I. Proteasomal and autophagic degradation systems. Annu Rev. Biochem 86, 193–224 (2017). · DOI · Paper page
  3. Saudou, F. & Humbert, S. The biology of huntingtin. Neuron 89, 910–926 (2016). · DOI · Paper page
  4. Ashkenazi, A. et al. Polyglutamine tracts regulate autophagy. Autophagy 13, 1613–1614 (2017). · DOI
  5. Marxreiter, F., Stemick, J. & Kohl, Z. Huntingtin lowering strategies. Int. J. Mol. Sci. 21, https://doi.org/10.3390/ijms21062146 (2020). · DOI
  6. van den Boom, J. & Meyer, H. VCP/p97-mediated unfolding as a principle in protein homeostasis and signalling. Mol. Cell 69, 182–194 (2018). · DOI · Paper page
  7. Ye, Y., Tang, W. K., Zhang, T. & Xia, D. A mighty “protein extractor” of the cell: structure and function of the p97/CDC48 ATPase. Front. Mol. Biosci. 4, 39 (2017). · DOI · Paper page
  8. Chou, T. F. & Deshaies, R. J. Quantitative cell-based protein degradation assays to identify and classify drugs that target the ubiquitin-proteasome system. J. Biol. Chem. 286, 16546–16554 (2011). · DOI · Paper page
  9. Bento, C. F. et al. Mammalian autophagy: how does it work. Annu. Rev. Biochem 85, 685–713 (2016). · DOI · Paper page
  10. Obara, K., Noda, T., Niimi, K. & Ohsumi, Y. Transport of phosphatidylinositol 3-phosphate into the vacuole via autophagic membranes in Saccharomyces cerevisiae. Genes Cells 13, 537–547 (2008). · DOI · Paper page
  11. Puri, C., Vicinanza, M. & Rubinsztein, D. C. Phagophores evolve from recycling endosomes. Autophagy 14, 1475–1477 (2018). · doi:10.1080/15548627.2018.1482148
  12. Mizushima, N., Sugita, H., Yoshimori, T. & Ohsumi, Y. A new protein conjugation system in human. The counterpart of the yeast Apg12p conjugation system essential for autophagy. J. Biol. Chem. 273, 33889–33892 (1998). · DOI · Paper page
  13. Kabeya, Y. et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 19, 5720–5728 (2000). · DOI · Paper page
  14. Hill, S. M. et al. VCP/p97 regulates Beclin-1-dependent autophagy initiation. Nat. Chem. Biol. https://doi.org/10.1038/s41589-020-00726-x (2021). · DOI
  15. Rubinsztein, D. C., Codogno, P. & Levine, B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat. Rev. Drug Disco. 11, 709–730 (2012). · DOI · Paper page
  16. Whitmarsh-Everiss, T. & Laraia, L. Small molecule probes for targeting autophagy. Nat. Chem. Biol. 17, 653–664 (2021). · DOI
  17. Geissler, E. K. The influence of mTOR inhibitors on immunity and the relationship to post-transplant malignancy. Transplant Res. 2, S2 (2013). · DOI
  18. Sarkar, S. et al. Small molecules enhance autophagy and reduce toxicity in Huntington’s disease models. Nat. Chem. Biol. 3, 331–338 (2007). · DOI · Paper page
  19. Tian, Y., Bustos, V., Flajolet, M. & Greengard, P. A small-molecule enhancer of autophagy decreases levels of Abeta and APP-CTF via Atg5-dependent autophagy pathway. FASEB J. 25, 1934–1942 (2011). · DOI · Paper page
  20. Darabi, S. et al. SMER28 attenuates dopaminergic toxicity mediated by 6-hydroxydopamine in the rats via modulating oxidative burdens and autophagy-related parameters. Neurochem. Res. 43, 2313–2323 (2018). · DOI
  21. Zhong, X., Ouyang, C., Liang, W., Dai, C. & Zhang, W. (2R,6R)-hydroxynorketamine alleviates electroconvulsive shock-induced learning impairment by inhibiting autophagy. Neuropsychiatr. Dis. Treat. 17, 297–304 (2021). · DOI
  22. VerPlank, J. J. S., Tyrkalska, S. D., Fleming, A., Rubinsztein, D. C. & Goldberg, A. L. cGMP via PKG activates 26S proteasomes and enhances degradation of proteins, including ones that cause neurodegenerative diseases. Proc. Natl. Acad. Sci. USA 117, 14220–14230 (2020). · DOI
  23. Katayama, H. et al. Visualizing and modulating mitophagy for therapeutic studies of neurodegeneration. Cell 181, 1176–1187.e1116 (2020). · DOI · Paper page
  24. Trettel, F. et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet. 9, 2799–2809 (2000). · DOI · Paper page
  25. Shen, D. et al. Novel cell- and tissue-based assays for detecting misfolded and aggregated protein accumulation within aggresomes and inclusion bodies. Cell Biochem. Biophys. 60, 173–185 (2011). · DOI · Paper page
  26. Beedham, C., Critchley, D. J. & Rance, D. J. Substrate specificity of human liver aldehyde oxidase toward substituted quinazolines and phthalazines: a comparison with hepatic enzyme from guinea pig, rabbit, and baboon. Arch. Biochem. Biophys. 319, 481–490 (1995). · DOI
  27. Chou, T. F. et al. Specific inhibition of p97/VCP ATPase and kinetic analysis demonstrate interaction between D1 and D2 ATPase domains. J. Mol. Biol. 426, 2886–2899 (2014). · DOI
  28. Lomenick, B. et al. Target identification using drug affinity responsive target stability (DARTS). Proc. Natl. Acad. Sci. USA 106, 21984–21989 (2009). · DOI · Paper page
  29. DeLaBarre, B. & Brunger, A. T. Complete structure of p97/valosin-containing protein reveals communication between nucleotide domains. Nat. Struct. Biol. 10, 856–863 (2003). · DOI · Paper page
  30. Magnaghi, P. et al. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat. Chem. Biol. 9, 548–556 (2013). · DOI · Paper page
  31. Zhou, H. J. et al. Discovery of a first-in-class, potent, selective, and orally bioavailable inhibitor of the p97 AAA ATPase (CB-5083. J. Med. Chem. 58, 9480–9497 (2015). · DOI · Paper page
  32. Ye, Y., Meyer, H. H. & Rapoport, T. A. Function of the p97-Ufd1-Npl4 complex in retrotranslocation from the ER to the cytosol: dual recognition of nonubiquitinated polypeptide segments and polyubiquitin chains. J. Cell Biol. 162, 71–84 (2003). · DOI · Paper page
  33. Zhang, X. et al. Altered cofactor regulation with disease-associated p97/VCP mutations. Proc. Natl Acad. Sci. USA 112, E1705–1714 (2015).
  34. Blythe, E. E., Gates, S. N., Deshaies, R. J. & Martin, A. Multisystem proteinopathy mutations in VCP/p97 increase NPLOC4·UFD1L binding and substrate processing. Structure 27, 1820–1829.e1824 (2019). · DOI · Paper page
  35. Wang, Q., Song, C., Yang, X. & Li, C. C. D1 ring is stable and nucleotide-independent, whereas D2 ring undergoes major conformational changes during the ATPase cycle of p97-VCP. J. Biol. Chem. 278, 32784–32793 (2003). · DOI
  36. Piazza, I. et al. A machine learning-based chemoproteomic approach to identify drug targets and binding sites in complex proteomes. Nat. Commun. 11, 4200 (2020). · DOI · Paper page
  37. Bago, R. et al. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase. Biochem J. 463, 413–427 (2014). · DOI · Paper page
  38. An, H. et al. TEX264 is an endoplasmic reticulum-resident ATG8-interacting protein critical for ER remodeling during nutrient stress. Mol. Cell 74, 891–908.e810 (2019). · DOI · Paper page
  39. Chino, H., Hatta, T., Natsume, T. & Mizushima, N. Intrinsically disordered protein TEX264 mediates ER-phagy. Mol. Cell 74, 909–921.e906 (2019). · DOI · Paper page
  40. Koukourakis, M. I. et al. SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy. Invest. New Drugs 36, 773–781 (2018). · DOI
  41. Figuerola-Conchas, A. et al. Small-molecule modulators of the ATPase VCP/p97 affect specific p97 cellular functions. ACS Chem. Biol. 15, 243–253 (2020). · DOI
  42. Marshall, R. S., Hua, Z., Mali, S., McLoughlin, F. & Vierstra, R. D. ATG8-binding uim proteins define a new class of autophagy adaptors and receptors. Cell 177, 766–781 e724 (2019). · DOI · Paper page
  43. Dantuma, N. P., Lindsten, K., Glas, R., Jellne, M. & Masucci, M. G. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat. Biotechnol. 18, 538–543 (2000). · DOI · Paper page
  44. Hänzelmann, P. & Schindelin, H. The interplay of cofactor interactions and post-translational modifications in the regulation of the AAA+ ATPase p97. Front. Mol. Biosci. 4, 21 (2017). · DOI · Paper page
  45. Bruderer, R. M., Brasseur, C. & Meyer, H. H. The AAA ATPase p97/VCP interacts with its alternative co-factors, Ufd1-Npl4 and p47, through a common bipartite binding mechanism. J. Biol. Chem. 279, 49609–49616 (2004). · DOI · Paper page
  46. Twomey, E. C. et al. Substrate processing by the Cdc48 ATPase complex is initiated by ubiquitin unfolding. Science 365, eaax1033 (2019). · DOI · Paper page
  47. Aviner, R. The science of puromycin: From studies of ribosome function to applications in biotechnology. Comput. Struct. Biotechnol. J. 18, 1074–1083 (2020). · DOI · Paper page
  48. Stevenson, J., Huang, E. Y. & Olzmann, J. A. Endoplasmic reticulum-associated degradation and lipid homeostasis. Annu Rev. Nutr. 36, 511–542 (2016). · DOI · Paper page
  49. Shih, Y. T. & Hsueh, Y. P. VCP and ATL1 regulate endoplasmic reticulum and protein synthesis for dendritic spine formation. Nat. Commun. 7, 11020 (2016). · DOI
  50. Song, C., Wang, Q. & Li, C. C. ATPase activity of p97-valosin-containing protein (VCP). D2 mediates the major enzyme activity, and D1 contributes to the heat-induced activity. J. Biol. Chem. 278, 3648–3655 (2003). · DOI · Paper page
  51. Banerjee, S. et al. 2.3 A resolution cryo-EM structure of human p97 and mechanism of allosteric inhibition. Science 351, 871–875 (2016). · DOI · Paper page
  52. Olszewski, M. M., Williams, C., Dong, K. C. & Martin, A. The Cdc48 unfoldase prepares well-folded protein substrates for degradation by the 26S proteasome. Commun. Biol. 2, 29 (2019). · DOI · Paper page
  53. Blythe, E. E., Olson, K. C., Chau, V. & Deshaies, R. J. Ubiquitin- and ATP-dependent unfoldase activity of P97/VCP•NPLOC4•UFD1L is enhanced by a mutation that causes multisystem proteinopathy. Proc. Natl. Acad. Sci. USA 114, E4380–E4388 (2017). · DOI · Paper page
  54. Bodnar, N. O. & Rapoport, T. A. Molecular mechanism of substrate processing by the Cdc48 ATPase complex. Cell 169, 722–735.e729 (2017). · DOI · Paper page
  55. Cooney, I. et al. Structure of the Cdc48 segregase in the act of unfolding an authentic substrate. Science 365, 502–505 (2019). · DOI · Paper page
  56. Halawani, D. et al. Hereditary inclusion body myopathy-linked p97/VCP mutations in the NH2 domain and the D1 ring modulate p97/VCP ATPase activity and D2 ring conformation. Mol. Cell Biol. 29, 4484–4494 (2009). · DOI · Paper page
  57. Niwa, H. et al. The role of the N-domain in the ATPase activity of the mammalian AAA ATPase p97/VCP. J. Biol. Chem. 287, 8561–8570 (2012). · DOI · Paper page
  58. Meyer, H. J. & Rape, M. Enhanced protein degradation by branched ubiquitin chains. Cell 157, 910–921 (2014). · DOI · Paper page
  59. Yau, R. G. et al. Assembly and function of heterotypic ubiquitin chains in cell-cycle and protein quality control. Cell 171, 918–933.e920 (2017). · DOI · Paper page
  60. Doulatov, S. et al. Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitors. Sci. Transl. Med. 9, https://doi.org/10.1126/scitranslmed.aah5645 (2017). · DOI · Paper page
  61. Korolchuk, V. I., Mansilla, A., Menzies, F. M. & Rubinsztein, D. C. Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol. Cell 33, 517–527 (2009). · DOI · Paper page
  62. He, R., Peng, J., Yuan, P., Xu, F. & Wei, W. Divergent roles of BECN1 in LC3 lipidation and autophagosomal function. Autophagy 11, 740–747 (2015). · DOI · Paper page
  63. Bento, C. F., Ashkenazi, A., Jimenez-Sanchez, M. & Rubinsztein, D. C. The Parkinson’s disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway. Nat. Commun. 7, 11803 (2016). · DOI · Paper page
  64. Hammond, G. R., Schiavo, G. & Irvine, R. F. Immunocytochemical techniques reveal multiple, distinct cellular pools of PtdIns4P and PtdIns(4,5)P(2). Biochem J. 422, 23–35 (2009). · DOI · Paper page
  65. Liu, J., Xu, Y., Stoleru, D. & Salic, A. Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin. Proc. Natl Acad. Sci. USA 109, 413–418 (2012). · DOI · Paper page
  66. Schmidt, E. K., Clavarino, G., Ceppi, M. & Pierre, P. SUnSET, a nonradioactive method to monitor protein synthesis. Nat. Methods 6, 275–277 (2009). · DOI · Paper page
  67. Weith, M. et al. Ubiquitin-independent disassembly by a p97 AAA-ATPase complex drives PP1 holoenzyme formation. Mol. Cell 72, 766–777.e766 (2018). · DOI · Paper page
  68. Lomenick, B., Jung, G., Wohlschlegel, J. A. & Huang, J. Target identification using drug affinity responsive target stability (DARTS). Curr. Protoc. Chem. Biol. 3, 163–180 (2011). · DOI · Paper page

Cited by

See all 49

Metadata

Authors
Wrobel, L., Hill, S. M., Djajadikerta, A., Fernandez-Estevez, M., Karabiyik, C., Ashkenazi, A., Barratt, V. J., Stamatakou, E., Gunnarsson, A., Rasmusson, T., Miele, E. W., Beaton, N., Bruderer, R., Feng, Y., Reiter, L., Castaldi, M. P., Jarvis, R., Tan, K., Bürli, R. W., & Rubinsztein, D. C.
Venue
Nature Communications
Published
2022-07-16
Volume
13
Issue
1
ISSN
2041-1723
Cited by
49
References
10
Language
en
Licence
Funders
UK Dementia Research Institute

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Compounds activating VCP D1 ATPase enhance both autophagic and proteasomal neurotoxic protein clearance. https://app.cochat.ai/papers/10.1038/s41467-022-31905-0
The paper
Wrobel, L., Hill, S. M., Djajadikerta, A., Fernandez-Estevez, M., Karabiyik, C., Ashkenazi, A., Barratt, V. J., Stamatakou, E., Gunnarsson, A., Rasmusson, T., Miele, E. W., Beaton, N., Bruderer, R., Feng, Y., Reiter, L., Castaldi, M. P., Jarvis, R., Tan, K., Bürli, R. W., & Rubinsztein, D. C. (2022). Compounds activating VCP D1 ATPase enhance both autophagic and proteasomal neurotoxic protein clearance. Nature Communications. https://doi.org/10.1038/s41467-022-31905-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.